VALEO news, videos and press releases
For more news please use our advanced search feature.
VALEO - More news...
VALEO - More news...
- Valeo - voting rights March 2025
- Valeo Shareholders' Meeting 2025
- Volkswagen Group cooperates with Valeo and Mobileye to enhance driver assistance in future MQB vehicles
- ***Valeo - 2024 results***
- Valeo and AWS Collaborate to Accelerate the Cloud-Native Revolution in Software-Defined Vehicles
- Voting rights - December 2024
- Voting rights - November 2024
- ROHM Semiconductor and Valeo Co-Develop the Next Generation of Power Electronics
- Voting rights - September 2024
- Acceleration of EVIG’s European Rollout: Clean Motion and Valeo Deepen Collaboration at Valeo New Mobility Center in Amiens
- Valeo H1 2024 Results
- Valeo Shareholders' Meeting 2024
- Valeo Q1 2024 Sales - First-quarter sales of 5.4 billion euros, up 2% like for like
- Valeo announces its green bond issue for an amount of 850 million euros with maturity April 2030
- Valeo General Shareholders' Meeting 2024
- Implementation of the share buy-back program
- Valeo presents Valeo Racer, a new extended reality in-car gaming experience developed with Unity, at South by Southwest 2024
- Valeo atteint ses objectifs 2023 et se fixe pour objectif d’augmenter de plus de 60 % son résultat d’exploitation et sa génération de cash entre 2023 et 2025
- Valeo is taking you for a ride @ SXSW 2024
- Valeo Q3 2023 Sales
- Valeo announces the sale of its propulsion systems business in Russia to NPK Avtopribor
- Cancel and replaces - Valeo H1 2023 results
- Valeo H1 2023 results
- Valeo General Shareholders' Meeting 2023
- Availability of the 2022 Universal Registration Document
- C2A Security Partners with Valeo to Enhance Cybersecurity for the Software Defined Vehicle
- C2A Security Partners with Valeo to Enhance Cybersecurity for the Software Defined Vehicle
- VALEO PHARMA ENTERS INTO CANADIAN COMMERCIAL SERVICES AGREEMENT WITH VERU FOR SABIZABULIN IN HOSPITALIZED ADULT PATIENTS WITH COVID-19 AT HIGH RISK FOR ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS)
- VALEO PHARMA OBTAINS PUBLIC REIMBURSEMENT FOR ENERZAIR® BREEZHALER® AND ATECTURA® BREEZHALER® IN ONTARIO, MANITOBA AND NEW BRUNSWICK
- VALEO PHARMA'S HESPERCO™ NOW AVAILABLE AT LOBLAWS, HESPERIDIN COVID-19 CLINICAL TRIAL RESULTS SUBMITTED FOR PUBLICATION
